ACNP - Italian Periodicals Catalogue

AAAAAA

ITA
ENG

Results: 1-14 |

Results: 14

Enrasentan improves survival, limits left ventricular remodeling, and preserves myocardial performance in hypertensive cardiac hypertrophy and dysfunction

Authors: Willette, RN Anderson, KM Nelson, AH Olzinski, AR Woods, T Coatney, RW Aiyar, N Ohlstein, EH Barone, FC

Citation: Rn. Willette et al., Enrasentan improves survival, limits left ventricular remodeling, and preserves myocardial performance in hypertensive cardiac hypertrophy and dysfunction, J CARDIO PH, 38(4), 2001, pp. 606-617

Activation of caspase-3/caspase-3-like activity in rat cardiomyocytes by an RGD peptide, but not the GPIIb/IIIa antagonist lotrafiban

Authors: Erhardt, JA Ohlstein, EH Toomey, JR Gabriel, MA Willette, RN Yue, TL Barone, FC Parsons, AA

Citation: Ja. Erhardt et al., Activation of caspase-3/caspase-3-like activity in rat cardiomyocytes by an RGD peptide, but not the GPIIb/IIIa antagonist lotrafiban, THROMB RES, 103(2), 2001, pp. 143-148

Pharmacology of SB-273779, a nonpeptide calcitonin gene-related peptide 1 receptor antagonist

Authors: Aiyar, N Daines, RA Disa, J Chambers, PA Sauermelch, VF Quiniou, MJ Khandoudi, N Gout, B Douglas, SA Willette, RN

Citation: N. Aiyar et al., Pharmacology of SB-273779, a nonpeptide calcitonin gene-related peptide 1 receptor antagonist, J PHARM EXP, 296(3), 2001, pp. 768-775

Hypertensive end-organ damage and premature mortality are p38 mitogen-activated protein kinase-dependent in a rat model of cardiac hypertrophy and dysfunction

Authors: Behr, TM Nerurkar, SS Nelson, AH Coatney, RW Woods, TN Sulpizio, A Chandra, S Brooks, DP Kumar, S Lee, JC Ohlstein, EH Angermann, CE Adams, JL Sisko, J Sackner-Bernstein, JD Willette, RN

Citation: Tm. Behr et al., Hypertensive end-organ damage and premature mortality are p38 mitogen-activated protein kinase-dependent in a rat model of cardiac hypertrophy and dysfunction, CIRCULATION, 104(11), 2001, pp. 1292-1298

Eprosartan reduces cardiac hypertrophy, protects heart and kidney, and prevents early mortality in severely hypertensive stroke-prone rats

Authors: Barone, FC Coatney, RW Chandra, S Sarkar, SK Nelson, AH Contino, LC Brooks, DP Campbell, WG Ohlstein, EH Willette, RN

Citation: Fc. Barone et al., Eprosartan reduces cardiac hypertrophy, protects heart and kidney, and prevents early mortality in severely hypertensive stroke-prone rats, CARDIO RES, 50(3), 2001, pp. 525-537

Identification and in vivo efficacy of small-molecule antagonists of integrin or alpha(v)beta(3) (the vitronectin receptor)

Authors: Miller, WH Keenan, RM Willette, RN Lark, MW

Citation: Wh. Miller et al., Identification and in vivo efficacy of small-molecule antagonists of integrin or alpha(v)beta(3) (the vitronectin receptor), DRUG DISC T, 5(9), 2000, pp. 397-408

Application of real-time polymerase chain reaction to quantitate induced expression of interleukin-1 beta mRNA in ischemic brain tolerance

Authors: Wang, XK Li, X Currie, RW Willette, RN Barone, FC Feuerstein, GZ

Citation: Xk. Wang et al., Application of real-time polymerase chain reaction to quantitate induced expression of interleukin-1 beta mRNA in ischemic brain tolerance, J NEUROSC R, 59(2), 2000, pp. 238-246

Human urotensin-II is a potent vasoactive peptide: Pharmacological characterization in the rat, mouse, dog and primate

Authors: Douglas, SA Ashton, DJ Sauermelch, CF Coatney, RW Ohlstein, DH Ruffolo, MR Ohlstein, EH Aiyar, NV Willette, RN

Citation: Sa. Douglas et al., Human urotensin-II is a potent vasoactive peptide: Pharmacological characterization in the rat, mouse, dog and primate, J CARDIO PH, 36, 2000, pp. S163-S166

Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey

Authors: Douglas, SA Sulpizio, AC Piercy, V Sarau, HM Ames, RS Aiyar, NV Ohlstein, EH Willette, RN

Citation: Sa. Douglas et al., Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey, BR J PHARM, 131(7), 2000, pp. 1262-1274

BMP-2 gene expression and effects on human vascular smooth muscle cells

Authors: Willette, RN Gu, JL Lysko, PG Anderson, KM Minehart, H Yue, TL

Citation: Rn. Willette et al., BMP-2 gene expression and effects on human vascular smooth muscle cells, J VASC RES, 36(2), 1999, pp. 120-125

The myocardial beta-adrenergic system in spontaneously hypertensive heart failure (SHHF) rats

Authors: Anderson, KM Eckhart, AD Willette, RN Koch, WJ

Citation: Km. Anderson et al., The myocardial beta-adrenergic system in spontaneously hypertensive heart failure (SHHF) rats, HYPERTENSIO, 33(1), 1999, pp. 402-407

Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14 (vol 401, pg 282, 1999)

Authors: Ames, RS Sarau, HM Chambers, JK Willette, RN Alyar, NV Romanic, AM Louden, CS Foley, JJ Sauermelch, CF Coatney, RW Ao, ZH Disa, J Holmes, SD Stadel, JM Martin, JD Liu, WS Glover, GI Wilson, S McNulty, DE Ellis, CE Elshourbagy, NA Shabon, U Trill, JJ Hay, DWP Ohlstein, EH Bergsma, DJ Douglas, SA

Citation: Rs. Ames et al., Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14 (vol 401, pg 282, 1999), NATURE, 402(6764), 1999, pp. 898-898

Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14

Citation: Rs. Ames et al., Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14, NATURE, 401(6750), 1999, pp. 282-286

In vitro and in vivo characterization of intrinsic sympathomimetic activity in normal and heart failure rats

Authors: Willette, RN Aiyar, N Yue, TL Mitchell, MP Disa, J Storer, BL Naselsky, DP Stadel, JM Ohlstein, EH Ruffolo, RR

Citation: Rn. Willette et al., In vitro and in vivo characterization of intrinsic sympathomimetic activity in normal and heart failure rats, J PHARM EXP, 289(1), 1999, pp. 48-53

Risultati: 1-14 |